Literature DB >> 19162069

Role of voltage-gated calcium channels in ascending pain pathways.

Gerald W Zamponi1, Richard J Lewis, Slobodan M Todorovic, Stephen P Arneric, Terrance P Snutch.   

Abstract

Voltage gated calcium channels (VGCCs) are well established mediators of pain signals in primary afferent neurons. N-type calcium channels are localized to synaptic nerve terminals in laminae 1 and 2 of the dorsal horn where their opening results in the release of neurotransmitters such as glutamate and substance P. The contribution of N-type channels to the processing of pain signals is regulated by alternate splicing of the N-type channel gene, with unique N-type channel splice variants being expressed in small nociceptive neurons. In contrast, T-type VGCCs of the Ca(v)3.2 subtype are likely localized to nerve endings where they regulate cellular excitability. Consequently, inhibition of N-type and Ca(v)3.2 T-type VGCCs has the propensity to mediate analgesia. T-type channel activity is regulated by redox modulation, and can be inhibited by a novel class of small organic blockers. N-type VGCC activity can be potently inhibited by highly selective peptide toxins that are delivered intrathecally, and the search for small organic blockers with clinical efficacy is ongoing. Here, we provide a brief overview of recent advances in this area, as presented at the Spring Pain Research conference (Grand Cayman, 2008).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19162069      PMCID: PMC2692704          DOI: 10.1016/j.brainresrev.2008.12.021

Source DB:  PubMed          Journal:  Brain Res Rev        ISSN: 0165-0173


  50 in total

1.  Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter.

Authors:  I A Sharpe; J Gehrmann; M L Loughnan; L Thomas; D A Adams; A Atkins; E Palant; D J Craik; D J Adams; P F Alewood; R J Lewis
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

2.  Mechanical and thermal antinociception in rats following systemic administration of mibefradil, a T-type calcium channel blocker.

Authors:  Slobodan M Todorovic; Adam Meyenburg; Vesna Jevtovic-Todorovic
Journal:  Brain Res       Date:  2002-10-04       Impact factor: 3.252

3.  The endogenous redox agent L-cysteine induces T-type Ca2+ channel-dependent sensitization of a novel subpopulation of rat peripheral nociceptors.

Authors:  Michael T Nelson; Pavle M Joksovic; Edward Perez-Reyes; Slobodan M Todorovic
Journal:  J Neurosci       Date:  2005-09-21       Impact factor: 6.167

Review 4.  Pharmacology of opioid and nonopioid analgesics in chronic pain states.

Authors:  T J Martin; J C Eisenach
Journal:  J Pharmacol Exp Ther       Date:  2001-12       Impact factor: 4.030

5.  Reversal of experimental neuropathic pain by T-type calcium channel blockers.

Authors:  Ahmet Dogrul; Luis R Gardell; Michael H Ossipov; F Cankat Tulunay; Josephine Lai; Frank Porreca
Journal:  Pain       Date:  2003-09       Impact factor: 6.961

6.  Enhanced excitability of sensory neurons in rats with cutaneous hyperalgesia produced by chronic compression of the dorsal root ganglion.

Authors:  J M Zhang; X J Song; R H LaMotte
Journal:  J Neurophysiol       Date:  1999-12       Impact factor: 2.714

7.  Mechanical and thermal hyperalgesia and ectopic neuronal discharge after chronic compression of dorsal root ganglia.

Authors:  X J Song; S J Hu; K W Greenquist; J M Zhang; R H LaMotte
Journal:  J Neurophysiol       Date:  1999-12       Impact factor: 2.714

8.  The novel N-type calcium channel blocker, AM336, produces potent dose-dependent antinociception after intrathecal dosing in rats and inhibits substance P release in rat spinal cord slices.

Authors:  Maree T Smith; Peter J Cabot; Fraser B Ross; Alan D Robertson; Richard J Lewis
Journal:  Pain       Date:  2002-03       Impact factor: 6.961

Review 9.  An update on electrophysiological studies in neuropathy.

Authors:  Christian Krarup
Journal:  Curr Opin Neurol       Date:  2003-10       Impact factor: 5.710

Review 10.  Chronic pain and medullary descending facilitation.

Authors:  Frank Porreca; Michael H Ossipov; G F Gebhart
Journal:  Trends Neurosci       Date:  2002-06       Impact factor: 13.837

View more
  70 in total

1.  A PEPTIDE UNCOUPLING CRMP-2 FROM THE PRESYNAPTIC Ca(2+) CHANNEL COMPLEX DEMONSTRATES EFFICACY IN ANIMAL MODELS OF MIGRAINE AND AIDS THERAPY-INDUCED NEUROPATHY.

Authors:  Matthew S Ripsch; Carrie J Ballard; May Khanna; Joyce H Hurley; Fletcher A White; Rajesh Khanna
Journal:  Transl Neurosci       Date:  2012-03       Impact factor: 1.757

Review 2.  Targeting voltage-gated calcium channels: developments in peptide and small-molecule inhibitors for the treatment of neuropathic pain.

Authors:  S Vink; P F Alewood
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

3.  Identification of CaV channel types expressed in muscle afferent neurons.

Authors:  Renuka Ramachandra; Bassil Hassan; Stephanie G McGrew; James Dompor; Mohamed Farrag; Victor Ruiz-Velasco; Keith S Elmslie
Journal:  J Neurophysiol       Date:  2013-07-10       Impact factor: 2.714

4.  Inhibition of transmitter release and attenuation of anti-retroviral-associated and tibial nerve injury-related painful peripheral neuropathy by novel synthetic Ca2+ channel peptides.

Authors:  Sarah M Wilson; Brian S Schmutzler; Joel M Brittain; Erik T Dustrude; Matthew S Ripsch; Jessica J Pellman; Tae-Sung Yeum; Joyce H Hurley; Cynthia M Hingtgen; Fletcher A White; Rajesh Khanna
Journal:  J Biol Chem       Date:  2012-08-13       Impact factor: 5.157

5.  Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca²⁺ channel complex.

Authors:  Joel M Brittain; Djane B Duarte; Sarah M Wilson; Weiguo Zhu; Carrie Ballard; Philip L Johnson; Naikui Liu; Wenhui Xiong; Matthew S Ripsch; Yuying Wang; Jill C Fehrenbacher; Stephanie D Fitz; May Khanna; Chul-Kyu Park; Brian S Schmutzler; Bo Myung Cheon; Michael R Due; Tatiana Brustovetsky; Nicole M Ashpole; Andy Hudmon; Samy O Meroueh; Cynthia M Hingtgen; Nickolay Brustovetsky; Ru-Rong Ji; Joyce H Hurley; Xiaoming Jin; Anantha Shekhar; Xiao-Ming Xu; Gerry S Oxford; Michael R Vasko; Fletcher A White; Rajesh Khanna
Journal:  Nat Med       Date:  2011-06-05       Impact factor: 53.440

Review 6.  Signaling complexes of voltage-gated calcium channels.

Authors:  Ray W Turner; Dustin Anderson; Gerald W Zamponi
Journal:  Channels (Austin)       Date:  2011-09-01       Impact factor: 2.581

Review 7.  Origins of antidromic activity in sensory afferent fibers and neurogenic inflammation.

Authors:  Linda S Sorkin; Kelly A Eddinger; Sarah A Woller; Tony L Yaksh
Journal:  Semin Immunopathol       Date:  2018-02-08       Impact factor: 9.623

Review 8.  Cellular and molecular mechanisms of pain.

Authors:  Allan I Basbaum; Diana M Bautista; Grégory Scherrer; David Julius
Journal:  Cell       Date:  2009-10-16       Impact factor: 41.582

Review 9.  Targeting voltage-gated calcium channels for neuropathic pain management.

Authors:  Danielle Perret; Z David Luo
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

10.  1,4-Dihydropyridine derivatives with T-type calcium channel blocking activity attenuate inflammatory and neuropathic pain.

Authors:  Chris Bladen; Vinicius M Gadotti; Miyase G Gündüz; N Daniel Berger; Rahime Şimşek; Cihat Şafak; Gerald W Zamponi
Journal:  Pflugers Arch       Date:  2014-07-03       Impact factor: 3.657

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.